The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Martha B. Maher, Kent R Bailey, H. Bryan Brewer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The reduction of elevated low density lipoprotein (LDL) cholesterol concentrations in patients with Type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents which may be of value in treating hypercholesterolemia are mevinolin and neomycin. Since these drugs lower cholesterol levels through complementary mechanisms, we evaluated the effects of mevinolin and combined mevinolin-neomycin treatment on plasma lipoprotein concentrations in 21 type II hyperlipoproteinemic patients. Mevinolin reduced total and LDL cholesterol concentrations by 24% and 31% respectively (P < 0.001) and 81% of the patients reduced their LDL cholesterol levels to less than 200 mg/dl. Although the addition of neomycin to mevinolin treatment further lowered total (5%) and LDL (4%) cholesterol concentrations, it also reduced HDL cholesterol levels (19%) (P < 0.05). Therefore mevinolin normalizes the plasma lipid concentrations in patients with type II hyperlipoproteinemia and combined mevinolin and neomycin treatment offers no advantage over mevinolin-only therapy. In addition, these findings emphasize the importance of determining the HDL cholesterol level to fully evaluate the effects of hypolipidemic therapy.

Original languageEnglish (US)
Pages (from-to)209-214
Number of pages6
JournalAtherosclerosis
Volume60
Issue number3
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Lovastatin
Hyperlipoproteinemia Type II
Neomycin
Lipoproteins
Lipids
LDL Cholesterol
HDL Cholesterol
Therapeutics
Hypercholesterolemia
Cholesterol
Morbidity
Mortality

Keywords

  • Cholesterol
  • High density lipoproteins
  • Hyperlipoproteinemia
  • Low density lipoproteins
  • Mevinolin
  • Neomycin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia. / Hoeg, Jeffrey M.; Maher, Martha B.; Bailey, Kent R; Brewer, H. Bryan.

In: Atherosclerosis, Vol. 60, No. 3, 1986, p. 209-214.

Research output: Contribution to journalArticle

@article{472069c19f3c4797b187003bb0199c6b,
title = "The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia",
abstract = "The reduction of elevated low density lipoprotein (LDL) cholesterol concentrations in patients with Type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents which may be of value in treating hypercholesterolemia are mevinolin and neomycin. Since these drugs lower cholesterol levels through complementary mechanisms, we evaluated the effects of mevinolin and combined mevinolin-neomycin treatment on plasma lipoprotein concentrations in 21 type II hyperlipoproteinemic patients. Mevinolin reduced total and LDL cholesterol concentrations by 24{\%} and 31{\%} respectively (P < 0.001) and 81{\%} of the patients reduced their LDL cholesterol levels to less than 200 mg/dl. Although the addition of neomycin to mevinolin treatment further lowered total (5{\%}) and LDL (4{\%}) cholesterol concentrations, it also reduced HDL cholesterol levels (19{\%}) (P < 0.05). Therefore mevinolin normalizes the plasma lipid concentrations in patients with type II hyperlipoproteinemia and combined mevinolin and neomycin treatment offers no advantage over mevinolin-only therapy. In addition, these findings emphasize the importance of determining the HDL cholesterol level to fully evaluate the effects of hypolipidemic therapy.",
keywords = "Cholesterol, High density lipoproteins, Hyperlipoproteinemia, Low density lipoproteins, Mevinolin, Neomycin",
author = "Hoeg, {Jeffrey M.} and Maher, {Martha B.} and Bailey, {Kent R} and Brewer, {H. Bryan}",
year = "1986",
doi = "10.1016/0021-9150(86)90167-X",
language = "English (US)",
volume = "60",
pages = "209--214",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia

AU - Hoeg, Jeffrey M.

AU - Maher, Martha B.

AU - Bailey, Kent R

AU - Brewer, H. Bryan

PY - 1986

Y1 - 1986

N2 - The reduction of elevated low density lipoprotein (LDL) cholesterol concentrations in patients with Type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents which may be of value in treating hypercholesterolemia are mevinolin and neomycin. Since these drugs lower cholesterol levels through complementary mechanisms, we evaluated the effects of mevinolin and combined mevinolin-neomycin treatment on plasma lipoprotein concentrations in 21 type II hyperlipoproteinemic patients. Mevinolin reduced total and LDL cholesterol concentrations by 24% and 31% respectively (P < 0.001) and 81% of the patients reduced their LDL cholesterol levels to less than 200 mg/dl. Although the addition of neomycin to mevinolin treatment further lowered total (5%) and LDL (4%) cholesterol concentrations, it also reduced HDL cholesterol levels (19%) (P < 0.05). Therefore mevinolin normalizes the plasma lipid concentrations in patients with type II hyperlipoproteinemia and combined mevinolin and neomycin treatment offers no advantage over mevinolin-only therapy. In addition, these findings emphasize the importance of determining the HDL cholesterol level to fully evaluate the effects of hypolipidemic therapy.

AB - The reduction of elevated low density lipoprotein (LDL) cholesterol concentrations in patients with Type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents which may be of value in treating hypercholesterolemia are mevinolin and neomycin. Since these drugs lower cholesterol levels through complementary mechanisms, we evaluated the effects of mevinolin and combined mevinolin-neomycin treatment on plasma lipoprotein concentrations in 21 type II hyperlipoproteinemic patients. Mevinolin reduced total and LDL cholesterol concentrations by 24% and 31% respectively (P < 0.001) and 81% of the patients reduced their LDL cholesterol levels to less than 200 mg/dl. Although the addition of neomycin to mevinolin treatment further lowered total (5%) and LDL (4%) cholesterol concentrations, it also reduced HDL cholesterol levels (19%) (P < 0.05). Therefore mevinolin normalizes the plasma lipid concentrations in patients with type II hyperlipoproteinemia and combined mevinolin and neomycin treatment offers no advantage over mevinolin-only therapy. In addition, these findings emphasize the importance of determining the HDL cholesterol level to fully evaluate the effects of hypolipidemic therapy.

KW - Cholesterol

KW - High density lipoproteins

KW - Hyperlipoproteinemia

KW - Low density lipoproteins

KW - Mevinolin

KW - Neomycin

UR - http://www.scopus.com/inward/record.url?scp=0022531823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022531823&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(86)90167-X

DO - 10.1016/0021-9150(86)90167-X

M3 - Article

C2 - 3524586

AN - SCOPUS:0022531823

VL - 60

SP - 209

EP - 214

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 3

ER -